Baxter International of Deerfield, Ill., announced that itspresident, Wilbur H. Gantz, will leave the company to becomefounder, president and chief executive officer of a newbiopharmaceutical and diagnostics company, Pathogenesis Corp.Baxter will hold an equity investment in the company andGantz will continue to serve on Baxter's board. James R. Tobin,Baxter executive vice president, has been named president andchief operating officer of Baxter.
Oncor Inc. has named Glen Paul Freiberg vice president ofclinical and regulatory affairs. Freiberg was group director forregulatory affairs and quality assurance for BoehringerMannheim Corp. Oncor (NASDAQ:ONCR) of Gaithersburg, Md.,manufactures and markets DNA probes.
Emisphere Technologies Inc. has appointed Dennis H. Penn vicepresident of business development. Penn was director of newproduct information and evaluations at Marion Merrell Dow.Emisphere (NASDAQ:EMIS) of Hawthorne, N.Y., is developing aproprietary oral drug delivery system.
Biogen Inc. (NASDAQ:BGEN) of Cambridge, Mass., has namedDaniel A. Cuoco vice president and general counsel. He wassenior vice president, general counsel and secretary of SquibbCorp.
Oxford GlycoSystems of Abingdon, England, has named GeoffBrooker finance director and promoted David Hadfield to vicepresident and director of marketing. Brooker was companysecretary for Celltech Group plc, a European biotechnologycompany. Oxford GlycoSystems is a supplier of glycobiology-related research tools.
Yair Devash has been appointed chairman of Future MedicalProducts Inc. of Hauppauge, N.Y. Devash directed retrovirologyresearch and development at Ortho Diagnostic Systems Inc.Future Medical (NASDAQ:FMPI) focuses on AIDS research,coronary disease treatment, drug detoxification and geneticenzymes.
Agouron Pharmaceuticals Inc. has named to its board A.E.Cohen, retired president of Merck Sharpe and DohmeInternational. Agouron (NASDAQ:AGPH) of San Diego designssynthetic drugs.
Daniel J. Paracka was elected a director of LidakPharmaceuticals Inc. Paracka was senior vice president offinance and chief financial officer of Rhone Poulenc Rorer Inc.Lidak (NASDAQ:LDAKA) of La Jolla, Calif., is commercializing itsLidakol treatment for herpes and other indications.
Walter L. Robb, senior vice president for corporate researchand development at General Electric, has been elected to theboard at Celgene Corp. The Warren, N.J., company(NASDAQ:CELG) is developing fine and specialty chemicals andbiotreatment systems.
(c) 1997 American Health Consultants. All rights reserved.